Caregiver Resources

Helpful Support Materials for Caregivers

Institution and advocacy network resources

From institution materials to advocacy networks, there are many resources you can access to be the caregiver your loved one needs. Below each group are suggested tools to help you with your care:


American Cancer Society

A nationwide, community-based voluntary health organization dedicated to eliminating cancer as a major health problem.


A national organization that provides free, professional support services and information to help people manage the emotional, practical, and financial challenges of cancer.

Metastatic Breast Cancer Info Center

For patients with metastatic breast cancer and their caregivers.

National Cancer Institute (NCI)

The NCI is the federal government's principal agency for cancer research and training.

Advocacy/Nonprofit groups

Cancer Support Community (CSC)

As the largest professionally led nonprofit network of cancer support worldwide, the CSC is dedicated to ensuring that all people impacted by cancer are empowered by knowledge, strengthened by action, and sustained by community.


LUNGevity is changing outcomes for people with lung cancer through research, education, and support.

Multiple Myeloma Research Foundation

Informed patients and caregivers are empowered to make informed decisions. Learn about multiple myeloma, the efforts that are being made to cure it, the resulting treatments that are available, and more.


The national not-for-profit organization offers support on their website for caregivers and their loved ones who are facing breast cancer.


The End of Prostate Cancer is a national nonprofit with the mission to end prostate cancer. ZERO advances research, and seeks to improve the lives of men and families, and inspire action.

Amgen does not endorse and is not responsible for the content included in these resources. Descriptions of resources are general and are summarized based on publicly available information provided by each organization. Amgen does not guarantee or is not responsible for the accuracy of the description of support/resources provided.

Important Safety Information

Do not take XGEVA® if you have low blood calcium (hypocalcemia). Your low blood calcium must be treated before you receive XGEVA®. XGEVA® can significantly lower the calcium levels in your blood and some deaths have been reported. Take calcium and vitamin D as your doctor tells you to. Tell your doctor right away if you experience spasms, twitches, cramps, or stiffness in your muscles or numbness or tingling in your fingers, toes, or around your mouth.

Do not take XGEVA® if you are allergic to denosumab or any of the ingredients of XGEVA®. Serious allergic reactions have happened in people who take XGEVA®. Call your doctor or go to your nearest emergency room right away if you have any symptoms of a serious allergic reaction, including low blood pressure (hypotension); trouble breathing; throat tightness; swelling of the face, lips, or tongue, rash; itching; or hives.

What is the most important information you should know about XGEVA®?

Do not take XGEVA® if you take Prolia. XGEVA® contains the same medicine as Prolia® (denosumab).

Severe jaw bone problems (osteonecrosis)

Unusual thigh bone fracture

Risk of high calcium levels in patients with Giant Cell Tumor of Bone and in patients who are still growing

Increased risk of broken bones in the spine after discontinuing XGEVA®

Possible harm to your unborn baby

Tell your doctor if you:

While taking XGEVA®, you should:

What are the possible side effects of XGEVA®?

These are not all the possible side effects of XGEVA®. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

Please see Full Prescribing Information.


XGEVA® is a prescription medicine used to prevent fracture, spinal cord compression, or the need for radiation or surgery to bone in patients with multiple myeloma and in patients with bone metastases from solid tumors.